BRAF and non-small cell lung carcinoma: These include targeting EGFR mutations and oncogenic ALK fusions in NSCLC with tyrosine kinase inhibitors,3, 4 and oncogenic BRAF mutations in melanoma and NSCLC with dabrafenib and trametinib.5 Thus, in the modern era, genomic characterization and drug development often progress in parallel to facilitate the rapid evaluation of novel pharmaceutical agents against newly identified, putative oncogenic drivers.6